Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
Member, St. Jude Faculty
Pharmaceutical Sciences
Clinton Stewart, PharmD
Pharmaceutical Sciences
MS313, Room D1052B
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: clinton.stewart@stjude.org
Phone: (901) 595-3665
FAX: (901) 525-6869
BSPh – Auburn University
PharmD - University of Tennessee, Memphis, TN
Improving Drug Therapy for Children with Brain Tumors
Fernandez CA, Smith C, Yang W, Lorier R, Crews KR, Kornegay N, Hicks JK, Stewart CF, Kawedia JD, Ramsey LB, Liu C, Evans WE, Relling MV, Broeckel U. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Therap, 2012.
Qaddoumi I, Billups CA, Tagen M, Stewart CF, Wu J, Helton K, McCarville MB, Merchant TE, Brennan R, Free TM, Given V, Haik BG, Rodriguez-Galindo C, Wilson MW. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer, 2012.
Kasow KA, Stewart CF, Barfield RC, Wright NL, Li C, Srivastava DK, Leung W, Horwitz EM, Bowman LC, Handgretinger R, Hale GA. A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up. Bone Marrow Transplant, 2012.
Bai F, Johnson J, Wang F, Yang L, Broniscer A, Stewart CF. Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879:2561-6, 2011. (PMCID: PMC3162072)
Elmeliegy MA, Carcaboso AM, L Chow LM, Zhang ZM, Calabrese C, Throm SL, Wang F, Baker SJ, Stewart CF. Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model. J Pharm Sci 100:4210-4214; 2011.
Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20:384-99, 2011. (PMCID: PMC3172881)
Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group Study. J Clin Oncol 29:4351-7, 2011. (PMCID: PMC3221519)
Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar A, Demuth T, Kun LE, Boyett JM, Gilbertson RJ. A phase I/II trial of MK0752 in children with refractory CNS malignancies: A Pediatric Brain Tumor Consortium Study. J Clin Oncol 29:3529-3534, 2011. (PMCID: PMC3179253)
Zhang F, Throm SL, Murley LL, Miller LA, Zatechka DS, Guy RK, Kennedy R, Stewart CF. MDM2 Antagonist Nutlin-3a Reverses Mitoxantrone Resistance by Inhibiting Breast Cancer Resistance Protein Mediated Drug Transport. Biochem Pharmacol 82:24-24, 2011. (PMCID: PMC3108438)
Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 17:89-99, 2011. (PMCID: PMC3017236)
Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, Dyer MA, Williams RT, Roussel MF, Nemeth K, Zhu F, Zhang J, Lu M, Panetta JC, Boulos N, Stewart CF. Whole-body physiologically-based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Disp 39:15-21, 2011. (PMCID: PMC3014266)
Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, Douglas JG, Kun LE, Boyett JM, Geyer JR. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium. Neuro Oncol 13:290-297, 2011. (PMCID: PMC3064605)
Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 28:4790-9, 2010. (PMCID: PMC3018345)
Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, Blaney SM, Packer RJ, Gururangan S, Banerjee A, Kieran MW, Kun LE, Gilbertson RJ, Boyett JM. A phase I and biology study study of geftinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer 46:3287-93, 2010. (PMCID: PMC2988095)
Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. A phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 28:4221-7, 2010. (PMCID: PMC2953974)
Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zweibel J, Blaney SM, Adamson PC. Pediatric phase I trial and pharmacokinetic study of vorinostat: Children’s Oncology Group Phase I Consortium Report. J Clin Oncol 28: 3623-3629, 2010. (PMCID: PMC2917318)
McKibbin T, Zhao W, Tagen M, Daw NC, Furman WL, McGregor LM, Geyer JR, Allen JW, Stewart CF. Epidermal Growth Factor Receptor Polymorphisms and Risk for Toxicity in Paediatric Patients Treated with Gefitinib. Eur J Cancer 46:2045-2051, 2010. (PMCID: PMC2904359)
McKibbin T, Panetta JC, Fouladi M, Gajjar A, Bai F, Okcu MF, Stewart CF. Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. Clin Cancer Res 16:1049-1057, 2010. (PMCID: PMC2818675)
Bai F, Zhu F, Tagen M, Miller L, Owens TS, Mallari J, Derrick E, Zhang F, Stewart CF. Determination of nutlin-3a in murine plasma by liquid chromatography ionization tandem mass spectrometry (LC-ESI-MS/MS). J Pharmaceutical Biomed Analysis 51:915-920, 2010. (PMCID: PMC2814893)
Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, Calabrese C, Tracy L, Waters CM, Stewart CF. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Research 70:4499-4508, 2010. (PMCID: PMC2880208)
Kennedy R, Groepper D, Tagen M, Christensen R, Navid F, Gajjar A, Stewart CF. Stability of cyclophosphamide in extemporaneous oral suspensions. Ann Pharmacother 44:295-301, 2010. (PMCID: PMC2835970)
Wilson MW, Fraga CH, Rodriquez-Galindo C, Hagedorn N, Leggas ML, Stewart C. Expression of the multi-drug resistance proteins and the pregnane X receptor in treated and untreated retinoblastoma. Current Eye Research 34:386-394, 2009.
Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF. Compartment-specific roles of ABC transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Research 69:5885-92, 2009. (PMCID: PMC2729173)
Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 27:4599-604, 2009. (PMCID: PMC2754908)
Shen J, Fraga C, Calabrese C, McCarville M, Schaiquevich P, Stewart CF. A modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse. J Pharmaceutical Sci 97:5013-5023, 2008.
Panetta JC, Schaiquevich P, Santana VM, Stewart CF. Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma. Clin Cancer Res 14:318-325, 2008.
Schaiquevich P, Panetta JC, Iacono LC, Freeman BB III, Santana VM, Gajjar A, Stewart CF. Population Pharmacokinetic Analysis of Topotecan in Pediatric Patients with Cancer. Clin Cancer Res 13:6703-6711, 2007.
Stewart CF, Panetta JC, O’Shaughnessy MA, Throm SL, Fraga CH, Owens T, Liu T, Billups C, Rodriguez-Galindo C, Gajjar A, Furman WL, McGregor LM. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 25:2594-2600, 2007.
Broniscer A, Panetta JC, O’Shaughnessy M, Fraga C, Bai F, Krasin M, Gajjar A, Stewart CF. Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420. Clin Cancer Res 13:1511-1515, 2007.
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart Clinton F, Dauser R, Sanford Robert A, Fuller Christine, Lau Ching, Boyett James M, Wallace Dana, Gilbertson Richard J. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncology 7:813-820, 2006.
Zhuang Y, Fraga CH, Hubbard KE, Hagedorn N, Panetta JC, Waters CM, Stewart CF. Topotecan CNS Penetration is Altered by a Tyrosine Kinase Inhibitor. Ca Research 66:11305-11313, 2006.
Spunt SL, Freeman BB III, Billups CA, McPherson V, Khan RB, Pratt CB, Stewart CF. A Phase I Clinical Trial of Oxaliplatin in Children and Adolescents with Refractory Solid Tumors. J Clin Oncol 25: 2274-2280, 2007.
Wilson MW, Fraga CH, Fuller CE, Rodriguez-Galindo C, Mancini J, Hagedorn N, Leggas ML, Stewart CF. Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest Ophthalmol Vis Sci 47:1269-1273, 2006.
Freeman BB III, Hinds PS, Iacono LC, Razzouk BI, Burghen E, Stewart CF. Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer. Pediatr Blood Cancer 47:572-579, 2006.
Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF. In vivo inhibition of multiple ABC transporters by an oral tyrosine kinase inhibitor. Cancer Res. 66:4802-4807, 2006.
Motl S, Zhuang Y, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumors. Clin Pharmacokinetics 45:871-903, 2006.
Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ and Stewart CF. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 23:4039-4047, 2005.
Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ, III, Gilbertson R, Germain GS, Harwood FC, Houghton PJ. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491-7499, 2004.
Stewart CF, Iacono LC, Chintagumpala M,Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar A. Results of a Phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor (PNET). J Clin Oncol 22:3357-3365, 2004.
Leggas M, Zhuang Y, Welden J, Self Z, Waters CM, Stewart CF. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. J Pharm Sci 93:2284-2295, 2004.
Panetta JC, Kirstein MN, Gajjar AJ, Nair G, Fouladi M, Stewart CF. A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Mathematical Biosci 186: 29-41, 2003.
Panetta JC, Iacono LC, Adamson PC, Stewart CF. The importance of pharmacokinetic limited sampling models for childhood cancer drug development. Clin Cancer Res 9:5068-5077, 2003.
Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, Houghton PJ, Stewart CF. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 9:633-640, 2003.
Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ. Direct translation of a protracted irinotecan schedule from xenograft model to Phase I trial in children. J Clin Oncol 17:1815-1824, 1999.
Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, Stewart CF. Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol 43:269-276, 1999.
Zamboni WC, Gajjar AJ, Mandrell TD, Einhaus SL, Danks MK, Rogers WP, Heideman RL, Houghton PJ, Stewart CF. A four hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma. Clin Cancer Res 4:2537-2544, 1998.
Zamboni WC, Stewart CF, Thompson J, Santana V, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505-511, 1998.
Furman WL, Baker SD, Pratt CB, Rivera G, Evans WE, Stewart CF. Escalating systemic exposure of topotecan following a 120-hr continuous infusion in children with relapsed acute leukemia. J Clin Oncol 14:1504-1511,1996.
Stewart CF, Baker SD, Crom WR, Heideman RL, Pratt CB. Clinical pharmacodynamics of topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946-1955, 1994.
Stewart CF, Arbuck SG, Fleming RA, Evans WE. Relation of systemic exposure to unbound etoposide and hematologic toxicity in adult cancer patients. Clin Pharmacol Ther 50:385-393, 1991.
Stewart CF, Fleming RA, Arbuck SG, Evans WE. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 50:6854-6856, 1990.
Stewart CF, Arbuck SG, Fleming RA, Evans WE. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 8:1874-1879, 1990.
Last update: August 2012
